Oncolytic Virus Engineering for Tumor Selectivity and Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic viruses used in cancer treatment face challenges in limiting replication and lytic damage to cancer cells while effectively mounting and maintaining a systemic anti-tumor immune response.
Innovation Solution
Development of oncolytic herpes simplex viruses modified to lack functional ICP34.5 and ICP47 genes, encoded with nucleic acids for heterologous dendritic cell growth factor FLT3L and cytokine IL12, utilizing a polycistronic linker element like P2A for co-expression, and optimized promoters and translation enhancers for enhanced immunostimulatory capacity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If oncolytic viruses are engineered to replicate in cancer cells, then tumor cell killing is enhanced, but systemic infection and damage to non-tumor cells increases
Solution Approach 1:
The virus is engineered with tumor-specific replication properties through deletion of ICP34.5 and ICP47 genes, making it replication-conditional. This allows the virus to selectively replicate and exert lytic effects only in tumor cells with specific metabolic characteristics (high glucose metabolism, elevated amino acid levels), while failing to replicate in normal cells. The local quality modification enables differential behavior in different cell types.
Solution Approach 2:
The viral genome is modified by deleting specific genes (ICP34.5 and ICP47) that regulate viral replication and pathogenicity. This parameter change in the viral genome structure creates a replication-conditional virus that can only replicate under specific conditions found in tumor cells, thereby limiting systemic infection while maintaining antitumor activity.
2Productivity
If oncolytic viruses are used to kill tumor cells, then direct antitumor effect is achieved, but systemic anti-tumor immune response is insufficient
Solution Approach 1:
The virus is engineered to simultaneously perform multiple functions: direct tumor cell lysis through replication and immune stimulation through cytokine expression. The co-expression of FLT3L (dendritic cell growth factor) and IL12 (potent immunostimulatory cytokine) merges the direct antitumor effect with immune activation, creating a dual-mechanism therapy that addresses both local tumor control and systemic immune response.
Solution Approach 2:
The virus acts as an intermediary carrier that delivers immunostimulatory cytokines (FLT3L and IL12) directly to the tumor microenvironment. These cytokines serve as mediators that bridge the gap between viral replication and immune activation, enhancing dendritic cell maturation and T cell responses while the virus replicates and lyses tumor cells.
3Reliability
If multiple cytokines are expressed in oncolytic virus, then immune stimulation is enhanced, but viral genome complexity and manufacturing difficulty increases
Solution Approach 1:
The viral genome is segmented into functional modules: the backbone HSV-1 genome provides replication and tumor selectivity, while separate expression cassettes encode FLT3L and IL12. The use of polycistronic arrangement with IRES elements allows multiple cytokines to be expressed from a single viral genome without requiring multiple independent transcriptional units, thereby managing genome complexity while achieving multi-cytokine expression.
Solution Approach 2:
The oncolytic virus is designed as a multi-functional platform that combines tumor-selective replication, direct cytolytic activity, and immunostimulation through multiple cytokines. This universal design allows a single viral construct to perform multiple therapeutic functions simultaneously, reducing the need for separate treatments and simplifying the overall therapy regimen despite the enhanced complexity of the viral genome.
Data Source
AI summary
The present invention relates to the use of oncolytic viruses (e.g., modified HSV-1 viruses) for the treatment of various types of cancer. In addition, the present invention relates to compositions and kits relating to such uses of oncolytic viruses.